Colorectal cancer (CRC) is one of the most frequent tumor entities worldwide with only
limited therapeutic options. CRC is not only a genetic disease with several mutations in …

Tumor microenvironment (TME) is a crucial regulator of tumor progression and cells in the
TME release a number of molecules that are responsible for anaplasticity, invasion …

Immune checkpoint blockade (ICB) therapy is a central pillar of melanoma treatment leading
to durable response rates. Important mechanisms of action of ICB therapy include …

Therapeutic options for metastatic colorectal cancer (mCRC) are very limited, and the
prognosis using combination therapy with a chemotherapeutic drug and a targeted agent …

Accumulating evidence has suggested the impact of senescence on tumor progression, but
no report has yet described how senescence shapes the tumor microenvironment of clear …

With the high morbidity and mortality, hepatocellular carcinoma (HCC) represents a major
yet growing burden for our global community. The relapse-prone nature and drug resistance …

An apparent paradox exists between the evidence for spontaneous systemic T cell-mediated
anti-tumor immune responses in cancer patients, observed particularly in their bone marrow …

Bladder cancer (BCa) is the 10th most commonly diagnosed cancer worldwide, and cellular
senescence is defined as a state of permanent cell cycle arrest and considered to play …

More than half of all patients with colorectal cancer (CRC) develop distant metastasis and,
depending on the local stage of the primary tumor, up to 48% of patients present peritoneal …

The evolution of preclinical in vitro cancer models has led to the emergence of human
cancer-on-chip or microphysiological analysis platforms (MAPs). Although it has numerous …